Matches in SemOpenAlex for { <https://semopenalex.org/work/W4299863881> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4299863881 endingPage "32" @default.
- W4299863881 startingPage "28" @default.
- W4299863881 abstract "(1) Seasonal allergic rhinitis, otherwise known as hayfever, is a harmless condition, although it can cause major discomfort and interfere with activities of daily living. We conducted a review of the literature, based on our in-house methodology, to determine the risk-benefits of treatments used in this setting. (2) Placebo-controlled trials show that sodium cromoglicate relieves symptoms, especially if it is used before symptoms appear. Adverse effects are rare with sodium cromoglicate nasal solutions and eye drops. (3) Nasal steroids have well-documented efficacy. Beclometasone is the best choice. Adverse effects include epistaxis, nasal irritation and, occasionally, systemic disorders. (4) Oral antihistamines are less effective than nasal steroids. They also provoke adverse effects, especially drowsiness. Nasal azelastine seems to have a similar efficacy as oral antihistamines. (5) The adverse effects of systemic steroids must not be overlooked, especially with long-term use. Oral administration is an alternative for severe symptoms that do not respond to other treatments, although this is rarely the case. Long-acting intramuscular steroids carry an increased risk of adverse effects. (6) Despite evaluation in several randomised controlled trials, there is no firm evidence that homeopathic preparations have any specific efficacy in allergic rhinitis. (7) Vasoconstrictors, ipratropium and montelukast, have negative risk-benefit balances in hay fever. (8) When a single allergen is responsible (grasses, ragweed, birch), clinical trials suggest that specific desensitisation can provide a modest improvement. However, this treatment carries a risk of local adverse effects, as well as a risk of rare but severe anaphylactic reactions, especially in patients who also have unstable severe asthma. (9) Sublingual desensitisation seems to be even less effective than subcutaneous desensitisation in adults. Follow-up is too short to know whether there is a risk of severe anaphylactic reactions. The results of paediatric studies are even less convincing. (10) In practice, when drug therapy is needed to relieve symptoms of seasonal allergic rhinitis, sodium cromoglicate is the first-line treatment. If a nasal steroid solution is chosen, it should be used for the shortest possible period." @default.
- W4299863881 created "2022-10-03" @default.
- W4299863881 date "2008-02-01" @default.
- W4299863881 modified "2023-10-18" @default.
- W4299863881 title "Seasonal allergic rhinitis: limited effectiveness of treatments." @default.
- W4299863881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18383656" @default.
- W4299863881 hasPublicationYear "2008" @default.
- W4299863881 type Work @default.
- W4299863881 citedByCount "0" @default.
- W4299863881 crossrefType "journal-article" @default.
- W4299863881 hasConcept C126322002 @default.
- W4299863881 hasConcept C141071460 @default.
- W4299863881 hasConcept C142724271 @default.
- W4299863881 hasConcept C16005928 @default.
- W4299863881 hasConcept C197934379 @default.
- W4299863881 hasConcept C203014093 @default.
- W4299863881 hasConcept C204787440 @default.
- W4299863881 hasConcept C27081682 @default.
- W4299863881 hasConcept C2776042228 @default.
- W4299863881 hasConcept C2776322731 @default.
- W4299863881 hasConcept C2776880894 @default.
- W4299863881 hasConcept C2777844070 @default.
- W4299863881 hasConcept C2777917907 @default.
- W4299863881 hasConcept C2778136109 @default.
- W4299863881 hasConcept C2778311950 @default.
- W4299863881 hasConcept C2780973058 @default.
- W4299863881 hasConcept C42219234 @default.
- W4299863881 hasConcept C71924100 @default.
- W4299863881 hasConcept C85663871 @default.
- W4299863881 hasConceptScore W4299863881C126322002 @default.
- W4299863881 hasConceptScore W4299863881C141071460 @default.
- W4299863881 hasConceptScore W4299863881C142724271 @default.
- W4299863881 hasConceptScore W4299863881C16005928 @default.
- W4299863881 hasConceptScore W4299863881C197934379 @default.
- W4299863881 hasConceptScore W4299863881C203014093 @default.
- W4299863881 hasConceptScore W4299863881C204787440 @default.
- W4299863881 hasConceptScore W4299863881C27081682 @default.
- W4299863881 hasConceptScore W4299863881C2776042228 @default.
- W4299863881 hasConceptScore W4299863881C2776322731 @default.
- W4299863881 hasConceptScore W4299863881C2776880894 @default.
- W4299863881 hasConceptScore W4299863881C2777844070 @default.
- W4299863881 hasConceptScore W4299863881C2777917907 @default.
- W4299863881 hasConceptScore W4299863881C2778136109 @default.
- W4299863881 hasConceptScore W4299863881C2778311950 @default.
- W4299863881 hasConceptScore W4299863881C2780973058 @default.
- W4299863881 hasConceptScore W4299863881C42219234 @default.
- W4299863881 hasConceptScore W4299863881C71924100 @default.
- W4299863881 hasConceptScore W4299863881C85663871 @default.
- W4299863881 hasIssue "93" @default.
- W4299863881 hasLocation W42998638811 @default.
- W4299863881 hasOpenAccess W4299863881 @default.
- W4299863881 hasPrimaryLocation W42998638811 @default.
- W4299863881 hasRelatedWork W1528358010 @default.
- W4299863881 hasRelatedWork W1999685532 @default.
- W4299863881 hasRelatedWork W2018077130 @default.
- W4299863881 hasRelatedWork W2018180109 @default.
- W4299863881 hasRelatedWork W2036269514 @default.
- W4299863881 hasRelatedWork W2408877015 @default.
- W4299863881 hasRelatedWork W2474348527 @default.
- W4299863881 hasRelatedWork W2592463167 @default.
- W4299863881 hasRelatedWork W2102888047 @default.
- W4299863881 hasRelatedWork W2276836119 @default.
- W4299863881 hasVolume "17" @default.
- W4299863881 isParatext "false" @default.
- W4299863881 isRetracted "false" @default.
- W4299863881 workType "article" @default.